Tyme Completes Enrollment in Phase 1b of Prostate Cancer Study for New Therapy Candidate

Tyme Completes Enrollment in Phase 1b of Prostate Cancer Study for New Therapy Candidate
Tyme Technologies has completed enrolling particpants in the Phase 1b portion of the open-label Phase 1b/2 clinical trial evaluating its lead investigational drug candidate SM-88 in non-metastatic prostate cancer patients with rising prostate-specific antigen (PSA) levels. The open-label, multi-center, dose-escalating, dose-expansion clinical trial (NCT02796898) is evaluating the effectiveness, safety, and drug properties of SM-88 in reducing PSA

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , , , .

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

Leave a Comment

Your email address will not be published. Required fields are marked *